Cover Image
市場調查報告書

PharmaPoint:氣喘 - 日本的醫藥品的預測與市場分析

PharmaPoint: Asthma - Japan Drug Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 314730
出版日期 內容資訊 英文 167 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:氣喘 - 日本的醫藥品的預測與市場分析 PharmaPoint: Asthma - Japan Drug Forecast and Market Analysis to 2023
出版日期: 2014年08月31日 內容資訊: 英文 167 Pages
簡介

氣喘是可藉由適當治療輕鬆預防的疾病,但仍造成全球一年25萬人死亡。氣喘的治療藥市場成長正在減緩,比較上效用較高的標準治療正在普及。今後生物學藥劑不僅可再度促成市場成長,預測氣喘的個別治療法之新時代即將揭開序幕。

本報告提供日本的氣喘治療藥市場相關調查分析,提供您疾病的概要與指南,競爭情形,主要藥物的詳細資訊(產品說明,安全性,有效性),SWOT分析,銷售額預測,影響分析(趨勢,推動因素·阻礙因素)等相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因·病理生理學
    • 病因
    • 病理生理學
    • 預後
    • QOL
  • 症狀

第4章 疾病的管理

  • 診斷和治療概要
  • 日本

第5章 競爭評估

  • 概要
  • 策略性競爭企業的評估
  • 吸入皮質類固醇藥
  • 長效型β受體激動劑
  • 吸入皮質類固醇藥/長效型β受體激動劑
  • 白三烯調節劑
  • 短效型β受體激動劑
  • 標靶治療
  • 抗膽鹼促效劑

第6章 未滿足需求和機會

  • 概要
  • 為控制嚴重氣喘的個別治療
  • 提升患者配合度
  • 低成本的氣喘藥
  • 兒童氣喘適當診斷

第7章 開發平台評估

  • 概要
  • 臨床開發中的潛力藥物

第8章 市場預測

  • 日本

第9章 附錄

圖表

目錄

Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented through appropriate treatment The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies in the late-stage pipeline.

The 2013 base-year market sales of asthma products in Japan were $1.7 billion. A dip in sales caused by the Singulair patent expiry in 2013, as well as the patent expiry of the best-selling ICS/LABA FDCs, GSK's Advair and AstraZeneca's Symbicort, will be offset by eight pipeline product launches, seven of which are targeted biologics. Despite the fact that the target patient pool for these biologic therapies will be relatively limited, as they will target only specific subpopulations of severe asthmatics, they will fulfill some of the major unmet needs for the treatment of severe asthmatics who do not respond to conventional treatment with the ICS and ICS/LABA therapies.

Scope

  • Overview of Asthma including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in Japan from 2013-2023.
  • Analysis of the impact of key events as well the drivers and restraints affecting the Japan Asthma market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Asthma.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2013-2023 in Japan.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
    • 3.1.3. Prognosis
    • 3.1.4. Quality of Life
  • 3.2. Symptoms

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Treatment Guidelines, Clinical Practice, and Leading Prescribed Drugs
    • 4.1.3. Clinical Practice
  • 4.2. Japan

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment
  • 5.3. Inhaled Corticosteroids
    • 5.3.1. Flovent (fluticasone propionate)
    • 5.3.2. Pulmicort (budenoside)
    • 5.3.3. Other Inhaled Corticosteroids
  • 5.4. Long-Acting Beta-Agonists
    • 5.4.1. Overview
  • 5.5. Inhaled Corticosteroids/Long-Acting Beta-Agonists
    • 5.5.1. Advair (fluticasone propionate/salmeterol xinafoate)
    • 5.5.2. Symbicort (budenoside/formoterol fumarate)
    • 5.5.3. Breo Ellipta (fluticasone furoate/vilanterol trifenatate)
    • 5.5.4. Flutiform (fluticasone propionate/formoterol fumarate)
  • 5.6. Leukotriene Modifiers
    • 5.6.1. Singulair (montelukast)
    • 5.6.2. Other Leukotriene Modifiers
  • 5.7. Short-Acting Beta-Agonists
    • 5.7.1. Overview
    • 5.7.2. Efficacy
    • 5.7.3. Safety
  • 5.8. Targeted Therapies
    • 5.8.1. Xolair (omalizumab)
  • 5.9. Anticholinergics
    • 5.9.1. Spiriva (tiotropium bromide)

6. Unmet Need and Opportunity

  • 6.1. Overview
  • 6.2. Personalized Therapies to Control Severe Asthma
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Better Patient Compliance
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Lower Cost of Asthma Medications
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Proper Diagnosis of Asthma in Children
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Drugs in Clinical Development
    • 7.2.1. Fluticasone furoate
    • 7.2.2. Cinquil (reslizumab)
    • 7.2.3. Bosatria (mepolizumab)
    • 7.2.4. Lebrikizumab
    • 7.2.5. Benralizumab
    • 7.2.6. Dupilumab
    • 7.2.7. Quilizumab
    • 7.2.8. Tralokinumab

8. Market Outlook

  • 8.1. Japan
    • 8.1.1. Forecast
    • 8.1.2. Key Events
    • 8.1.3. Drivers and Barriers - Global Issues
    • 8.1.4. Drivers and Barriers

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed Asthma Patients
    • 9.4.2. Percent Drug-Treated Patients
    • 9.4.3. Drugs Included in Each Therapeutic Class
    • 9.4.4. Key Launch and Patent Expiry Dates
    • 9.4.5. General Pricing Assumptions
    • 9.4.6. Individual Drug Assumptions
    • 9.4.7. Generic Erosion
    • 9.4.8. Pricing of Pipeline Agents
  • 9.5. Physicians and Specialists Included in This Study
  • 9.6. About the Authors
    • 9.6.1. Author
    • 9.6.2. Author/Reviewer
    • 9.6.3. Reviewer
    • 9.6.4. Global Head of Healthcare
  • 9.7. About GlobalData
  • 9.8. Disclaimer

List of Tables

  • Table 1: Symptoms of Asthma
  • Table 2: Treatment Guidelines for Asthma by Country
  • Table 3: Most Prescribed Drugs for Asthma by Class and Disease Severity in the Global Markets, 2013
  • Table 4: Dosing of Common ICSs for Adult Asthma Therapy to Achieve Equivalent Therapeutic Potency
  • Table 5: Recommended Low Daily Dose of ICSs in Children with Asthma Under Five Years of Age
  • Table 6: Country Profile, Asthma Management - Japan
  • Table 7: Leading Treatments for Asthma, 2014
  • Table 8: Product Profile - Flovent
  • Table 9: Efficacy - Flovent Diskus Versus Placebo
  • Table 10: Adverse Events Related to Flovent Diskus
  • Table 11: Flovent SWOT Analysis, 2014
  • Table 12: Product Profile - Pulmicort
  • Table 13: Pulmicort-Associated Adverse Events
  • Table 14: Pulmicort SWOT Analysis, 2014
  • Table 15: Summary of Other Marketed ICSs for Asthma Treatment, 2014
  • Table 16: Product Profile - Advair
  • Table 17: Efficacy - Advair Diskus Versus Its Individual Components
  • Table 18: Advair, Frequency of Drug-Related Adverse Events
  • Table 19: Advair SWOT Analysis, 2014
  • Table 20: Product Profile - Symbicort
  • Table 21: Efficacy - Symbicort Versus Its Individual Components
  • Table 22: Symbicort, Frequency of Drug-Related Adverse Events
  • Table 23: Symbicort SWOT Analysis, 2014
  • Table 24: Product Profile - Breo Ellipta
  • Table 25: Efficacy - Breo Ellipta Versus Flovent
  • Table 26: Safety - Breo Ellipta Versus Flovent
  • Table 27: Breo Ellipta SWOT Analysis, 2014
  • Table 28: Product Profile - Flutiform
  • Table 29: Efficacy - Flutiform Versus Advair
  • Table 30: Safety - Flutiform Versus Advair
  • Table 31: Flutiform SWOT Analysis, 2014
  • Table 32: Product Profile - Singulair
  • Table 33: Efficacy - Singulair+Pulmicort Versus Double-Dose of Pulmicort
  • Table 34: Safety of Singulair+Pulmicort Compared With a Double Dose of Pulmicort
  • Table 35: Singulair SWOT Analysis, 2014
  • Table 36: Overview of the Leading SABAs for Asthma Treatment, 2014
  • Table 37: Efficacy - Nebulized Levalbuterol Versus Nebulized Albuterol
  • Table 38: Adverse Events Related to Nebulized Levalbuterol and Nebulized Albuterol
  • Table 39: Product Profile - Xolair
  • Table 40: Efficacy - Xolair Versus Placebo
  • Table 41: Xolair SWOT Analysis, 2014
  • Table 42: Product Profile - Spiriva
  • Table 43: Efficacy - Spiriva's Versus LABA and Double-Dose ICS
  • Table 44: Adverse Events Related to the Use of Spiriva
  • Table 45: Spiriva SWOT Analysis, 2014
  • Table 46: Unmet Need and Opportunity in Asthma
  • Table 47: Asthma - Late Stage Pipeline, 2014
  • Table 48: Product Profile - Fluticasone Furoate
  • Table 49: Fluticasone Fuorate Efficacy Versus Placebo and Fluticasone Propionate
  • Table 50: Fluticasone Furoate Safety Profile
  • Table 51: Fluticasone Furoate SWOT Analysis, 2014
  • Table 52: Product Profile - Cinquil
  • Table 53: Efficacy of Cinquil Versus Placebo
  • Table 54: Cinquil's Safety Profile
  • Table 55: Cinquil SWOT Analysis, 2014
  • Table 56: Product Profile - Bosatria
  • Table 57: Efficacy of Bosatria Versus Placebo
  • Table 58: Bosatria's Safety Profile
  • Table 59: Bosatria SWOT Analysis, 2012
  • Table 60: Product Profile - Lebrikizumab
  • Table 61: Efficacy of Lebrikizumab Versus Placebo
  • Table 62: Lebrikizumab Safety Profile
  • Table 63: Lebrikizumab SWOT Analysis, 2014
  • Table 64: Product Profile - Benralizumab
  • Table 65: Efficacy of Benralizumab Versus Placebo
  • Table 66: Benralizumab SWOT Analysis, 2014
  • Table 67: Product Profile - Dupilumab
  • Table 68: Efficacy of Dupilumab Versus Placebo
  • Table 69: Dupilumab's Safety Profile
  • Table 70: Dupilumab SWOT Analysis, 2014
  • Table 71: Product Profile - Quilizumab
  • Table 72: Efficacy of Quilizumab Versus Placebo
  • Table 73: Quilizumab SWOT Analysis, 2014
  • Table 74: Product Profile - Tralokinumab
  • Table 75: Efficacy of Tralokinumab Versus Placebo
  • Table 76: Tralokinumab's Safety Profile
  • Table 77: Tralokinumab SWOT Analysis, 2014
  • Table 78: Sales Forecast ($m) for Asthma in Japan, 2013-2023
  • Table 79: Key Events Impacting Sales for Asthma in Japan, 2013-2023
  • Table 80: Global Asthma Market - Drivers and Barriers, 2014
  • Table 81: Asthma Market - Drivers and Barriers in Japan, 2013-2023
  • Table 82: Key Launch Dates
  • Table 83: Key Patent Expiries
  • Table 84: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1:Stepwise Disease Management Approach for Asthma in Adults
  • Figure 2: Stepwise Disease Management Approach for Asthma in Children Age Five and Younger
  • Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in Asthma, 2013-2023
  • Figure 4: Sales for Asthma in Japan by Drug Class, 2013-2023
Back to Top